Substrate-modulated cytochrome P450 17A1 and cytochrome b5 interactions revealed by NMR

Journal of Biological Chemistry

Volumn 288, Issue 23, 2013, Pages 17008-17018

  Estrada, D Fernando ^a   Laurence, Jennifer S ^a   Scott, Emily E ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATALYTIC DOMAINS; COMPLEX FORMATIONS; DIFFERENTIAL EFFECT; MEDIATED REACTIONS; NADPH-CYTOCHROME P450 REDUCTASE; NMR CHEMICAL SHIFTS; REACTION CONDITIONS; REVERSIBLE BINDING;

COMMUNICATION; PROTEINS;

SUBSTRATES;

CYTOCHROME B5; CYTOCHROME P450 17; CYTOCHROME P450 17A1; LYASE; OXYGENASE; UNCLASSIFIED DRUG;

ALLOSTERISM; ARTICLE; BINDING SITE; CATALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVE SITE; ENZYME SUBSTRATE; GENE MAPPING; MUTAGENESIS; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; STEROID HYDROXYLATION;

CYTOCHROME B5; CYTOCHROME P450 17A1; ENZYME MECHANISMS; NMR; PROTEIN CONFORMATION; PROTEIN-PROTEIN INTERACTIONS; STEROIDOGENESIS;

17-ALPHA-HYDROXYPREGNENOLONE; AMINO ACID SUBSTITUTION; CATALYTIC DOMAIN; CYTOCHROMES B5; HUMANS; MULTIENZYME COMPLEXES; MUTAGENESIS; MUTATION, MISSENSE; NADP; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN STRUCTURE, QUATERNARY; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84878750608     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.468926     Document Type: Article

References (48)

1. Ortiz de Montellano, P. R. (2005) Cytochrome P450. Structure, Mechanism, and Biochemistry, 3rd ed., pp. 133-134 and 448-450, Kluwer Academic/Plenum Publishers, New York
2. 5. Pharmacol. Ther. 97, 139-152
3. Im, S. C., and Waskell, L. (2011) The interaction of microsomal cytochrome P450 2B4 with its redox partners, cytochrome P450 reductase and cytochrome b(5). Arch. Biochem. Biophys. 507, 144-153
4. 5 increases the rate of product formation by cytochrome P450 2B4 and competes with cytochrome P450 reductase for a binding site on cytochrome P450 2B4. J. Biol. Chem. 282, 29766-29776
5. Akhtar, M. K., Kelly, S. L., and Kaderbhai, M. A. (2005) Cytochrome b(5) modulation of 17α-hydroxylase and 17-20 lyase (CYP17) activities in steroidogenesis. J. Endocrinol. 187, 267-274 (Pubitemid 41685186)
6. 5 inhibits electron transfer from NADPH-cytochrome P450 reductase to ferric cytochrome P450 2B4. J. Biol. Chem. 283, 5217-5225
7. 5 on the formation of products in cytochrome P-450-catalyzed reactions. Drug Metab. Dispos. 14, 89-96
8. 5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer. J. Biol. Chem. 273, 3158-3165
9. 5 or heme oxygenase. J. Biol. Chem. 276, 30885-30891
10. 5 and cytochrome P450 reductase. J. Biol. Chem. 273, 17036-17049
11. Miller, W. L., Geller, D. H., and Auchus, R. J. (1998) The molecular basis of isolated 17,20 lyase deficiency. Endocr. Res. 24, 817-825 (Pubitemid 29016484)
12. Hall, P. F. (1991) Cytochrome P-450 C21scc. One enzyme with two actions. Hydroxylase and lyase. J. Steroid Biochem. Mol. Biol. 40, 527-532
13. Akhtar, M., Wright, J. N., and Lee-Robichaud, P. (2011) A review of mechanistic studies on aromatase (CYP19) and 17α-hydroxylase-17,20-lyase (CYP17). J. Steroid Biochem. Mol. Biol. 125, 2-12
14. 5 in the biosynthesis of androgens by human P450c17. Arch. Biochem. Biophys. 317, 343-347
15. 5 in neonatal rhesus macaques. Endocrinology 150, 1748-1756
16. New, M. I. (1970) Male pseudohermaphroditism due to 17 α-hydroxylase deficiency. J. Clin. Invest. 49, 1930-1941
17. Liu, Y., Dettin, L. E., Folmer, J., Zirkin, B. R., and Papadopoulos, V. (2007) Abnormal morphology of spermatozoa in cytochrome P450 17α-hydroxylase/17, 20-lyase (CYP17) deficient mice. J. Androl. 28, 453-460 (Pubitemid 46662968)
18. Zamaratskaia, G., Lou, Y., Peacock, J., Rydhmer, L., Andersson, H. K., Juneja, R. K., Chen, G., Lundström, K., and Squires, E. J. (2008) Effect of polymorphism in the porcine cytochrome bα (CYB5A) gene on androstenone and skatole concentrations and sexual development in Swedish pig populations. Animal 2, 190-196 (Pubitemid 351598571)
19. Geller, D. H., Auchus, R. J., Mendonça, B. B., and Miller, W. L. (1997) The genetic and functional basis of isolated 17,20-lyase deficiency. Nat. Genet. 17, 201-205
20. Geller, D. H., Auchus, R. J., and Miller, W. L. (1999) P450c17 mutations R347H and R358Q selectively disrupt 17,20-lyase activity by disrupting interactions with P450 oxidoreductase and cytochrome b5. Mol. Endocrinol. 13, 167-175 (Pubitemid 29022289)
21. DeVore, N. M., and Scott, E. E. (2012) Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature 482, 116-119
22. Banci, L., Bertini, I., Ferroni, F., and Rosato, A. (1997) Solution structure of reduced microsomal rat cytochrome b5. Eur. J. Biochem. 249, 270-279 (Pubitemid 27432621)
23. 5 requires residues Glu-48 and Glu-49 to stimulate the 17,20-lyase activity of cytochrome P450c17. Biochemistry 45, 755-762
24. Zhao, C., Gao, Q., Roberts, A. G., Shaffer, S. A., Doneanu, C. E., Xue, S., Goodlett, D. R., Nelson, S. D., and Atkins, W. M. (2012) Cross-linking mass spectrometry and mutagenesis confirm the functional importance of surface interactions between CYP3A4 and holo/apo cytochrome b(5). Biochemistry 51, 9488-9500
25. Peng, H. M., and Auchus, R. J. (2013) The action of cytochrome b(5) on both CYP2E1 and CYP2C19 activities requires the anionic residues D58 and D65. Biochemistry 52, 210-220
26. 5. Biochem. J. 321, 857-863
27. 5 by mass spectrometry and site-directed mutagenesis. J. Biol. Chem. 281, 20404-20417
28. 5 in the process. Arch. Biochem. Biophys. 314, 234-241
29. 5 in yeast and characterization of mutants of the membrane-anchoring domain. J. Biol. Chem. 267, 12583-12591
30. Gilep, A. A., Guryev, O. L., Usanov, S. A., and Estabrook, R. W. (2001) Reconstitution of the enzymatic activities of cytochrome P450s using recombinant flavocytochromes containing rat cytochrome b(5) fused to NADPH-cytochrome P450 reductase with various membrane-binding segments. Arch. Biochem. Biophys. 390, 215-221 (Pubitemid 32568483)
31. 5 interacts with cytochrome P450 via nonspecific interactions. Biochim. Biophys. Acta 1674, 319-326
32. 5. J. Biomol. NMR 47, 289-295
33. Pechurskaya, T. A., Lukashevich, O. P., Gilep, A. A., and Usanov, S. A. (2008) Engineering, expression, and purification of "soluble" human cytochrome P45017α and its functional characterization. Biochemistry Biokhimiia 73, 806-811
34. Shen, A. L., Porter, T. D., Wilson, T. E., and Kasper, C. B. (1989) Structural analysis of the FMN binding domain of NADPH-cytochrome P-450 oxidoreductase by site-directed mutagenesis. J. Biol. Chem. 264, 7584-7589 (Pubitemid 19119176)
35. Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J., and Bax, A. (1995) NMRPipe. A multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277-293
36. Johnson, B. A. (2004) Using NMRView to visualize and analyze the NMR spectra of macromolecules. Methods Mol. Biol. 278, 313-352
37. 5 to promote male sex-hormone biosynthesis. Biochem. J. 342, 309-312
38. Lin, D., Zhang, L. H., Chiao, E., and Miller, W. L. (1994) Modeling and mutagenesis of the active site of human P450c17. Mol. Endocrinol. 8, 392-402 (Pubitemid 24108366)
39. Sherbet, D. P., Tiosano, D., Kwist, K. M., Hochberg, Z., and Auchus, R. J. (2003) CYP17 mutation E305G causes isolated 17,20-lyase deficiency by selectively altering substrate binding. J. Biol. Chem. 278, 48563-48569 (Pubitemid 41079494)
40. Attard, G., Reid, A. H., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., Clark, J., Cooper, C. S., Kaye, S. B., Dearnaley, D., Lee, G., and de Bono, J. S. (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563-4571
41. de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Jr., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., Patterson, H., Hainsworth, J. D., Ryan, C. J., Sternberg, C. N., Ellard, S. L., Fléchon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C. M., Scher, H. I., and COU-AA-301 Investigators. (2011) Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005
42. Attard, G., Reid, A. H., Olmos, D., and de Bono, J. S. (2009) Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res. 69, 4937-4940
43. O'Donnell, A., Judson, I., Dowsett, M., Raynaud, F., Dearnaley, D., Mason, M., Harland, S., Robbins, A., Halbert, G., Nutley, B., and Jarman, M. (2004) Hormonal impact of the 17α-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 90, 2317-2325 (Pubitemid 38961894)
44. Durley, R. C., and Mathews, F. S. (1996) Refinement and structural analysis of bovine cytochrome b5 at 1.5 A resolution. Acta Crystallogr. D Biol. Crystallogr. 52, 65-76 (Pubitemid 3019160)
45. Miller, W. L. (2012) The syndrome of 17,20 lyase deficiency. J. Clin. Endocrinol. Metab. 97, 59-67
46. Xia, C., Panda, S. P., Marohnic, C. C., Martásek, P., Masters, B. S., and Kim, J. J. (2011) Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency. Proc. Natl. Acad. Sci. U.S.A. 108, 13486-13491
47. Yanagibashi, K., and Hall, P. F. (1986) Role of electron transport in the regulation of the lyase activity of C21 side-chain cleavage P-450 from porcine adrenal and testicular microsomes. J. Biol. Chem. 261, 8429-8433 (Pubitemid 17202723)
48. 5-dependent acyl-carbon cleavage activities. J. Steroid. Biochem. Mol. Biol. 92, 119-130